Bath Savings Trust Co lowered its stake in CVS Health Corp (NYSE:CVS) by 11.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,659 shares of the pharmacy operator’s stock after selling 1,071 shares during the quarter. Bath Savings Trust Co’s holdings in CVS Health were worth $704,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Jackson Grant Investment Advisers Inc. increased its stake in CVS Health by 0.6% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock worth $232,000 after purchasing an additional 18 shares in the last quarter. Elefante Mark B increased its stake in CVS Health by 0.7% in the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock worth $515,000 after purchasing an additional 45 shares in the last quarter. Traynor Capital Management Inc. increased its stake in CVS Health by 1.3% in the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock worth $290,000 after purchasing an additional 48 shares in the last quarter. Sequoia Financial Advisors LLC increased its stake in CVS Health by 0.8% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock worth $515,000 after purchasing an additional 53 shares in the last quarter. Finally, Brookstone Capital Management increased its stake in CVS Health by 1.8% in the 2nd quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock worth $254,000 after purchasing an additional 55 shares in the last quarter. 82.24% of the stock is currently owned by hedge funds and other institutional investors.

In related news, COO Jonathan C. Roberts sold 85,743 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $83.14, for a total value of $7,128,673.02. Following the completion of the sale, the chief operating officer now directly owns 119,555 shares in the company, valued at approximately $9,939,802.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Thomas M. Moriarty sold 20,547 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $81.17, for a total value of $1,667,799.99. Following the completion of the sale, the executive vice president now owns 43,178 shares of the company’s stock, valued at $3,504,758.26. The disclosure for this sale can be found here. 0.61% of the stock is owned by insiders.

Shares of CVS Health Corp (NYSE:CVS) opened at $73.08 on Friday. The stock has a market capitalization of $71,719.84, a PE ratio of 12.40, a PEG ratio of 1.33 and a beta of 0.89. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05. CVS Health Corp has a 1-year low of $66.45 and a 1-year high of $84.72.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. The business had revenue of $46.18 billion during the quarter, compared to analyst estimates of $46.17 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The firm’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.64 EPS. sell-side analysts anticipate that CVS Health Corp will post 5.9 earnings per share for the current year.

A number of brokerages recently weighed in on CVS. Royal Bank of Canada began coverage on CVS Health in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price target on the stock. Jefferies Group lifted their target price on CVS Health from $82.00 to $86.00 and gave the company a “hold” rating in a research note on Friday, September 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of CVS Health in a research note on Sunday, September 10th. Oppenheimer reaffirmed a “buy” rating and set a $95.00 target price on shares of CVS Health in a research note on Monday, October 9th. Finally, Mizuho set a $90.00 target price on CVS Health and gave the company a “buy” rating in a research note on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $86.35.

TRADEMARK VIOLATION WARNING: “CVS Health Corp (CVS) Shares Sold by Bath Savings Trust Co” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/12/16/cvs-health-corp-cvs-shares-sold-by-bath-savings-trust-co.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Stock Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related stocks with our FREE daily email newsletter.